ES2960206T3 - Células madre mesenquimales como adyuvantes de vacunas y métodos para utilizar las mismas - Google Patents

Células madre mesenquimales como adyuvantes de vacunas y métodos para utilizar las mismas Download PDF

Info

Publication number
ES2960206T3
ES2960206T3 ES17709498T ES17709498T ES2960206T3 ES 2960206 T3 ES2960206 T3 ES 2960206T3 ES 17709498 T ES17709498 T ES 17709498T ES 17709498 T ES17709498 T ES 17709498T ES 2960206 T3 ES2960206 T3 ES 2960206T3
Authority
ES
Spain
Prior art keywords
adjuvant
vaccine
cells
mesenchymal stem
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17709498T
Other languages
English (en)
Spanish (es)
Inventor
Joshua M Hare
Ana Marie Landin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Longeveron Inc
Original Assignee
Longeveron Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Longeveron Inc filed Critical Longeveron Inc
Application granted granted Critical
Publication of ES2960206T3 publication Critical patent/ES2960206T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES17709498T 2016-02-04 2017-02-02 Células madre mesenquimales como adyuvantes de vacunas y métodos para utilizar las mismas Active ES2960206T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662291350P 2016-02-04 2016-02-04
PCT/US2017/016200 WO2017136539A1 (en) 2016-02-04 2017-02-02 Mesenchymal stem cells as vaccine adjuvants and methods for using the same

Publications (1)

Publication Number Publication Date
ES2960206T3 true ES2960206T3 (es) 2024-03-01

Family

ID=58261704

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17709498T Active ES2960206T3 (es) 2016-02-04 2017-02-02 Células madre mesenquimales como adyuvantes de vacunas y métodos para utilizar las mismas

Country Status (11)

Country Link
US (2) US11975068B2 (https=)
EP (2) EP4316497A3 (https=)
JP (3) JP7814090B2 (https=)
KR (1) KR20180105705A (https=)
AU (2) AU2017213812B2 (https=)
CA (1) CA3013457A1 (https=)
ES (1) ES2960206T3 (https=)
IL (1) IL260858B (https=)
SG (1) SG11201806587RA (https=)
WO (1) WO2017136539A1 (https=)
ZA (2) ZA201805159B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020166063A1 (ja) * 2019-02-15 2020-08-20 大和薬品株式会社 フレイル改善方法およびフレイル改善食品
CN111568927A (zh) * 2020-05-23 2020-08-25 湖南源品细胞生物科技有限公司 一种msc用于调节记忆b细胞数量的应用
JP2023540096A (ja) 2020-09-08 2023-09-21 ロングエバーオン インコーポレイテッド アロジェニック間葉系幹細胞によるアルツハイマー病の治療
CN112641938A (zh) * 2020-11-22 2021-04-13 翁炳焕 一种dna重组干细胞载体新冠疫苗
US20220218817A1 (en) * 2021-01-08 2022-07-14 Vitro Biopharma, Inc. Immune modulation by mesenchymal stem cells
CN117999082A (zh) 2021-07-26 2024-05-07 美商生命科学有限公司 间充质干细胞在治疗青少年左心发育不良综合征中的用途
WO2025137077A1 (en) 2023-12-19 2025-06-26 Longeveron, Inc. Improved brain architecture and biomarkers in alzheimer's disease with mesenchymal stem cells
WO2025199451A2 (en) 2024-03-21 2025-09-25 Longeveron Inc. Mmp-14 potency assay for mesenchymal stem cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2999199A (en) 1998-04-03 1999-10-25 Osiris Therapeutics, Inc. Mesenchymal stem cells as immunosuppressants
US8554280B2 (en) 2010-03-23 2013-10-08 Ebay Inc. Free-form entries during payment processes
US10472647B2 (en) 2012-12-21 2019-11-12 The Administrators Of The Tulane Educational Fund Primary mesenchymal stem cells as a vaccine platform
WO2014100857A1 (en) 2012-12-24 2014-07-03 Cell Ideas Pty Ltd Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
US9101597B2 (en) 2013-03-14 2015-08-11 The Administration Of The Tulane Educational Fund Immunoprotective primary mesenchymal stem cells and methods
CN104138391B (zh) 2013-05-08 2018-07-31 中国科学院上海生命科学研究院 间充质干细胞在预防或治疗应激反应导致的免疫力下降中的应用

Also Published As

Publication number Publication date
CA3013457A1 (en) 2017-08-10
JP2026012755A (ja) 2026-01-27
JP2023036949A (ja) 2023-03-14
EP3411050B1 (en) 2023-09-27
WO2017136539A1 (en) 2017-08-10
AU2017213812B2 (en) 2024-04-04
SG11201806587RA (en) 2018-09-27
EP4316497A2 (en) 2024-02-07
JP2019509264A (ja) 2019-04-04
US20190038742A1 (en) 2019-02-07
AU2024204598A1 (en) 2024-07-18
ZA202000574B (en) 2021-08-25
EP3411050A1 (en) 2018-12-12
ZA201805159B (en) 2020-10-28
EP4316497A3 (en) 2024-05-01
US11975068B2 (en) 2024-05-07
IL260858B (en) 2022-04-01
AU2017213812A1 (en) 2018-08-16
IL260858A (en) 2018-10-31
US20240252627A1 (en) 2024-08-01
KR20180105705A (ko) 2018-09-28
JP7814090B2 (ja) 2026-02-16

Similar Documents

Publication Publication Date Title
ES2960206T3 (es) Células madre mesenquimales como adyuvantes de vacunas y métodos para utilizar las mismas
Jabbari et al. Secondary memory CD8+ T cells are more protective but slower to acquire a central–memory phenotype
Coccia et al. Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity
CN115811986A (zh) 冠状病毒疫苗
Plotkin Vaccination against cytomegalovirus, the changeling demon
ES2643943T3 (es) Potenciación de la capacidad de las células presentadoras de antígeno humanas para estimular células T tanto in vitro como in vivo y su uso en la vacunación
Ross et al. Single dose combination nanovaccine provides protection against influenza A virus in young and aged mice
TWI820753B (zh) 使用人類間葉幹細胞以實現細胞性及體液性免疫的方法
Graalmann et al. B cell depletion impairs vaccination-induced CD8+ T cell responses in a type I interferon-dependent manner
RS58891B1 (sr) Uslovno replicirajući citomegalovirus kao vakcina za cmv
BRPI0614265A2 (pt) uso de uma vacina do vìrus da febre amarela e de uma vacina de flavivìrus quimérico e kit contendo referidas vacinas
Tsai et al. Exosome-mediated mRNA delivery for SARS-CoV-2 vaccination
Khan et al. Asymptomatic memory CD8+ T cells: from development and regulation to consideration for human vaccines and immunotherapeutics
Gellin et al. Measles: state of the art and future directions
ES2546612T3 (es) Vacuna contra la viruela
ES2240417T3 (es) Procedimiento para la preparacion de vacunas mediante la utilizacion de celulas hibridas.
MXPA03009515A (es) Vacunas que incluyen como adyuvante ifn del tipo i, y procesos relacionados con ellas.
Adam et al. A modified porous silicon microparticle promotes mucosal delivery of SARS-CoV-2 antigen and induction of potent and durable systemic and mucosal T helper 1 skewed protective immunity
Lee et al. The efficacy of inactivated split respiratory syncytial virus as a vaccine candidate and the effects of novel combination adjuvants
Ivanova et al. Anti-Asialo GM1 treatment during secondary Toxoplasma gondii infection is lethal and depletes T cells
López-Gómez et al. Mesoporous silicon microparticles enhance antiviral immunity and memory responses against SARS-CoV-2
Awais et al. Covid-19 vaccines and their adequacy prospects in Pakistani population; A comparative review
HK40109512A (zh) 使用人类间充质干细胞以实现细胞免疫及体液免疫的方法
Reinke et al. BCG enables protection against malaria through adjuvanting an Adenovirus-vectored vaccine
Gasper Cell-Mediated Antiviral Immunity And Host Responses to CD8 T-cell Vaccines and Respiratory Virus Infection